Table 4.
Factors indicating poor prognosis (bold text) in all 28 patients who died within 30 days. Typically, at least twofactors were present, e.g. poor performance status and numerous brain metastases. Four patients had less thantwo factors
| Cancer type | RT | Incomplete | PT control | Non-brain metastases | Active sites incl. primary | KPS | Number (brain) | Symptoms | Int (mo.) | Age (yrs.) | EC-S | LabBM | OS (mo.) | Cause of death | Factors <2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Esophagus | WB30 | 1 | 1 | hep, oss, lym | 3 | 6 | 3 | 1 | 6 | 70 | 2 | 2.5 | 0.3 | extracran | |
| Melanoma | WB30 | 0 | 0 | pul, hep, lym | 4 | 6 | 5 | 1 | 0 | 62 | 1 | 0 | 0.8 | intracran | |
| NSCLC | WB30 | 1 | 0 | pul, hep, adr, oss, lym | 5 | 8 | 2 | 1 | 0 | 69 | 1 | 0 | 0.4 | extracran | |
| Jejunum | WB20 | 0 | 0 | pul, hep, adr, oth | 5 | 7 | 6 | 1 | 0 | 67 | 3 | 3 | 1.0 | extracran | |
| NSCLC | WB20 | 0 | 0 | pul, adr, oss, lym | 5 | 5 | 2 | 0 | 0 | 63 | 3 | 3 | 0.5 | extracran | |
| NSCLC | WB20 | 0 | 0 | 0 | 1 | 6 | 4 | 1 | 5 | 69 | 1 | 1.5 | 0.4 | unk | |
| NSCLC | WB20 | 0 | 1 | oss, adr, oth | 3 | 5 | 7 | 1 | 3 | 64 | 2 | 2.5 | 0.6 | extracran | |
| Kidney | WB30 | 1 | 0 | hep, oss, adr, pul | 5 | 6 | 5 | 1 | 2 | 56 | 2 | 2 | 0.6 | unk | |
| NSCLC | WB30 | 0 | 1 | pul | 1 | 5 | 6 | 1 | 3 | 55 | 1 | 1.5 | 0.8 | unk | |
| Kidney | WB30 | 1 | 0 | oss, pul | 3 | 6 | 4 | 1 | 35 | 63 | 2 | 1.5 | 0.1 | extracran | |
| NSCLC | WB30 | 0 | 0 | pul | 2 | 6 | 4 | 1 | 4 | 66 | 2 | 3 | 0.7 | extracran | |
| ER + Her2 - | WB30 | 0 | 1 | pul, lym, adr | 3 | 7 | 7 | 1 | 70 | 67 | 1 | 0 | 1.0 | extracran | |
| NSCLC | WB30 | 0 | 0 | adr, oss | 3 | 7 | 17 | 1 | 0 | 53 | 2 | 1 | 1.0 | extracran | |
| NSCLC | WB20 | 0 | 0 | hep, adr, lym | 4 | 5 | 4 | 0 | 5 | 65 | 3 | 3 | 0.7 | extracran | |
| Bladder | WB30 | 0 | 1 | oss, adr, lym | 3 | 7 | 2 | 1 | 38 | 74 | 1 | 1.5 | 0.7 | unk | <2 |
| NSCLC | WB20 | 0 | 1 | pul | 1 | 7 | 4 | 1 | 22 | 65 | 1 | 1.5 | 0.5 | extracran | <2 |
| Melanoma | WB30 | 0 | 1 | pul, oss, lym | 3 | 7 | 18 | 1 | 8 | 77 | 2 | 1 | 1.0 | intracran | |
| Bladder | WB30 | 0 | 0 | pul, oss, lym | 4 | 6 | 9 | 1 | 25 | 75 | 1 | 2 | 1.0 | extracran | |
| Melanoma | WB30 | 0 | 1 | pul, lym, ski | 3 | 5 | 6 | 1 | 6 | 55 | 3 | 1.5 | 0.7 | unk | |
| NSCLC | SRS | 0 | 1 | Pul | 1 | 7 | 1 | 1 | 3 | 75 | 1 | 2 | 0.8 | extracran | <2 |
| ER+ Her2- | WB30 | 1 | 1 | hep, pul, oss, oth | 4 | 5 | 12 | 1 | 154 | 74 | 3 | 3 | 0.3 | unk | |
| SCLC | CTx | 1 | 0 | Oss | 2 | 6 | 50 | 1 | 0 | 82 | 0 | 0 | 0.1 | unk | |
| Esophagus | WB30 | 1 | 1 | lym, adr, oss | 3 | 5 | 8 | 1 | 6 | 72 | 2 | 1 | 0.1 | unk | |
| NSCLC | SFRT | 0 | 0 | hep, oss, pul | 4 | 5 | 1 | 1 | 0 | 66 | 3 | 3 | 0.7 | extracran | |
| NSCLC | SFRT | 1 | 0 | hep, pul | 3 | 7 | 1 | 1 | 0 | 93 | 2 | 2.5 | 0.1 | extracran | <2 |
| Rectum | WB30 | 1 | 0 | pul, lym, oth | 4 | 6 | 10 | 1 | 10 | 48 | 1 | 1.5 | 0.1 | extracran | |
| NSCLC | WB30 | 0 | 0 | 0 | 1 | 6 | 5 | 1 | 0 | 76 | 0 | 0.5 | 0.7 | extracran | |
| NSCLC | WB30 | 0 | 0 | hep, oss | 3 | 7 | 4 | 1 | 18 | 51 | 2 | 2 | 0.7 | extracran |
Bold text is utilized to identify those parameters that indicate a poor prognosis. Regular text indicates parameters unrelated to prognosis
RT radiotherapy, PT primary tumor, KPS Karnofsky performance status, Int time interval between cancer diagnosis and brain metastases, EC-S extracranial score, LabBM LabBM score, OS overall survival.
NSCLC non-small cell lung cancer, ER + Her2- breast cancer (estrogen receptor positive, Her2 negative), SCLC small cell lung cancer, WB30 whole-brain radiotherapy 30 Gy, WB20 whole-brain radiotherapy 20 Gy, SRS radiosurgery, CTx chemotherapy, SFRT stereotactic fractionated radiotherapy, hep liver, oss bone, lym lymphatic, pul lung, adr adrenal glands, oth other, ski skin, unk extracranial progression, but brain metastases might have contributed as well.